This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Drusano, G. L.
Right arrow Articles by Craig, W. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Drusano, G. L.
Right arrow Articles by Craig, W. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2001, p. 13-22, Vol. 45, No. 1
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.1.13-22.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Use of Preclinical Data for Selection of a Phase II/III Dose for Evernimicin and Identification of a Preclinical MIC Breakpoint

G. L. Drusano,1,* S. L. Preston,1 C. Hardalo,2 R. Hare,2 C. Banfield,2 D. Andes,3 O. Vesga,3 and W. A. Craig3

Division of Clinical Pharmacology, Albany Medical College, Albany, New York1; Schering Plough Research Institute, Kenilworth, New Jersey2; and Division of Clinical Pharmacology, University of Wisconsin, Madison, Wisconsin3

Received 22 November 1999/Returned for modification 26 April 2000/Accepted 1 September 2000

One of the most challenging issues in the design of phase II/III clinical trials of antimicrobial agents is dose selection. The choice is often based on preclinical data from pharmacokinetic (PK) studies with animals and healthy volunteers but is rarely linked directly to the target organisms except by the MIC, an in vitro measure of antimicrobial activity with many limitations. It is the thesis of this paper that rational dose-selection decisions can be made on the basis of the pharmacodynamics (PDs) of the test agent predicted by a mathematical model which uses four data sets: (i) the distribution of MICs for clinical isolates, (ii) the distribution of the values of the PK parameters for the test drug in the population, (iii) the PD target(s) developed from animal models of infection, and (iv) the protein binding characteristics of the test drug. In performing this study with the new anti-infective agent evernimicin, we collected a large number (n = 4,543) of recent clinical isolates of gram-positive pathogens (Streptococcus pneumoniae, Enterococcus faecalis and Enterococcus faecium, and Staphylococcus aureus) and determined the MICs using E-test methods (AB Biodisk, Stockholm, Sweden) for susceptibility to evernimicin. Population PK data were collected from healthy volunteers (n = 40) and patients with hypoalbuminemia (n = 12), and the data were analyzed by using NPEM III. PD targets were developed with a neutropenic murine thigh infection model with three target pathogens: S. pneumoniae (n = 5), E. faecalis (n = 2), and S. aureus (n = 4). Drug exposure or the ratio of the area under the concentration-time curve/MIC (AUC/MIC) was found to be the best predictor of microbiological efficacy. There were three possible microbiological results: stasis of the initial inoculum at 24 h (107 CFU), log killing (pathogen dependent, ranging from 1 to 3 log10), or 90% maximal killing effect (90% Emax). The levels of protein binding in humans and mice were similar. The PK and PD of 6 and 9 mg of evernimicin per kg of body weight were compared; the population values for the model parameters and population covariance matrix were used to generate five Monte Carlo simulations with 200 subjects each. The fractional probability of attaining the three PD targets was calculated for each dose and for each of the three pathogens. All differences in the fractional probability of attaining the target AUC/MIC in this PD model were significant. For S. pneumoniae, the probability of attaining all three PD targets was high for both doses. For S. aureus and enterococci, there were increasing differences between the 6- and 9-mg/kg evernimicin doses for reaching the 2 log killing (S. aureus), 1 log killing (enterococci), or 90% Emax AUC/MIC targets. This same approach may also be used to set preliminary in vitro MIC breakpoints.

* Corresponding author. Mailing address: Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Albany Medical College, 47 New Scotland Ave., Albany, NY 12208. Phone: (518) 262-6330. Fax: (518) 262-6333. E-mail: GLDRUSANO{at}AOL.COM.

Antimicrobial Agents and Chemotherapy, January 2001, p. 13-22, Vol. 45, No. 1
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.1.13-22.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • MacGowan, A. P., Reynolds, R., Noel, A. R., Bowker, K. E. (2009). Bacterial Strain-to-Strain Variation in Pharmacodynamic Index Magnitude, a Hitherto Unconsidered Factor in Establishing Antibiotic Clinical Breakpoints. Antimicrob. Agents Chemother. 53: 5181-5184 [Abstract] [Full Text]  
  • van den Anker, J. N., Pokorna, P., Kinzig-Schippers, M., Martinkova, J., de Groot, R., Drusano, G. L., Sorgel, F. (2009). Meropenem Pharmacokinetics in the Newborn. Antimicrob. Agents Chemother. 53: 3871-3879 [Abstract] [Full Text]  
  • Gumbo, T., Siyambalapitiyage Dona, C. S. W., Meek, C., Leff, R. (2009). Pharmacokinetics-Pharmacodynamics of Pyrazinamide in a Novel In Vitro Model of Tuberculosis for Sterilizing Effect: a Paradigm for Faster Assessment of New Antituberculosis Drugs. Antimicrob. Agents Chemother. 53: 3197-3204 [Abstract] [Full Text]  
  • Andes, D., Craig, W., Nielsen, L. A., Kristensen, H. H. (2009). In Vivo Pharmacodynamic Characterization of a Novel Plectasin Antibiotic, NZ2114, in a Murine Infection Model. Antimicrob. Agents Chemother. 53: 3003-3009 [Abstract] [Full Text]  
  • DeFife, R., Scheetz, M. H., Feinglass, J. M., Postelnick, M. J., Scarsi, K. K. (2009). Effect of Differences in MIC Values on Clinical Outcomes in Patients with Bloodstream Infections Caused by Gram-Negative Organisms Treated with Levofloxacin. Antimicrob. Agents Chemother. 53: 1074-1079 [Abstract] [Full Text]  
  • Crandon, J. L, Kuti, J. L, Jones, R. N, Nicolau, D. P (2009). Comparison of 2002-2006 OPTAMA Programs for US Hospitals: Focus on Gram-Negative Resistance. The Annals of Pharmacotherapy 43: 220-227 [Abstract] [Full Text]  
  • Ambrose, P. G., Forrest, A., Craig, W. A., Rubino, C. M., Bhavnani, S. M., Drusano, G. L., Heine, H. S. (2007). Pharmacokinetics-Pharmacodynamics of Gatifloxacin in a Lethal Murine Bacillus anthracis Inhalation Infection Model. Antimicrob. Agents Chemother. 51: 4351-4355 [Abstract] [Full Text]  
  • Rodriguez-Tudela, J. L., Almirante, B., Rodriguez-Pardo, D., Laguna, F., Donnelly, J. P., Mouton, J. W., Pahissa, A., Cuenca-Estrella, M. (2007). Correlation of the MIC and Dose/MIC Ratio of Fluconazole to the Therapeutic Response of Patients with Mucosal Candidiasis and Candidemia. Antimicrob. Agents Chemother. 51: 3599-3604 [Abstract] [Full Text]  
  • Muller, A. E., DeJongh, J., Bult, Y., Goessens, W. H. F., Mouton, J. W., Danhof, M., van den Anker, J. N. (2007). Pharmacokinetics of Penicillin G in Infants with a Gestational Age of Less than 32 Weeks. Antimicrob. Agents Chemother. 51: 3720-3725 [Abstract] [Full Text]  
  • Landersdorfer, C. B., Kirkpatrick, C. M. J., Kinzig-Schippers, M., Bulitta, J. B., Holzgrabe, U., Drusano, G. L., Sorgel, F. (2007). Population Pharmacokinetics at Two Dose Levels and Pharmacodynamic Profiling of Flucloxacillin. Antimicrob. Agents Chemother. 51: 3290-3297 [Abstract] [Full Text]  
  • Vinks, A. A., van Rossem, R. N., Mathot, R. A. A., Heijerman, H. G. M., Mouton, J. W. (2007). Pharmacokinetics of Aztreonam in Healthy Subjects and Patients with Cystic Fibrosis and Evaluation of Dose-Exposure Relationships Using Monte Carlo Simulation. Antimicrob. Agents Chemother. 51: 3049-3055 [Abstract] [Full Text]  
  • Turnidge, J., Paterson, D. L. (2007). Setting and Revising Antibacterial Susceptibility Breakpoints. Clin. Microbiol. Rev. 20: 391-408 [Abstract] [Full Text]  
  • Bulitta, J. B., Duffull, S. B., Kinzig-Schippers, M., Holzgrabe, U., Stephan, U., Drusano, G. L., Sorgel, F. (2007). Systematic Comparison of the Population Pharmacokinetics and Pharmacodynamics of Piperacillin in Cystic Fibrosis Patients and Healthy Volunteers. Antimicrob. Agents Chemother. 51: 2497-2507 [Abstract] [Full Text]  
  • Meagher, A. K., Passarell, J. A., Cirincione, B. B., Van Wart, S. A., Liolios, K., Babinchak, T., Ellis-Grosse, E. J., Ambrose, P. G. (2007). Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Skin and Skin-Structure Infections. Antimicrob. Agents Chemother. 51: 1939-1945 [Abstract] [Full Text]  
  • Hope, W. W., Warn, P. A., Sharp, A., Howard, S., Kasai, M., Louie, A., Walsh, T. J., Drusano, G. L., Denning, D. W. (2006). Derivation of an In Vivo Drug Exposure Breakpoint for Flucytosine against Candida albicans and Impact of the MIC, Growth Rate, and Resistance Genotype on the Antifungal Effect. Antimicrob. Agents Chemother. 50: 3680-3688 [Abstract] [Full Text]  
  • Tam, V. H., Kabbara, S., Yeh, R. F., Leary, R. H. (2006). Impact of Sample Size on the Performance of Multiple-Model Pharmacokinetic Simulations. Antimicrob. Agents Chemother. 50: 3950-3952 [Abstract] [Full Text]  
  • Bakker-Woudenberg, I. A. J. M., ten Kate, M. T., Goessens, W. H. F., Mouton, J. W. (2006). Effect of Treatment Duration on Pharmacokinetic/Pharmacodynamic Indices Correlating with Therapeutic Efficacy of Ceftazidime in Experimental Klebsiella pneumoniae Lung Infection.. Antimicrob. Agents Chemother. 50: 2919-2925 [Abstract] [Full Text]  
  • Tam, V. H., Adams, S., Larocco, M. T., Gerard, L. N., Gentry, L. O., Garey, K. W. (2006). An integrated pharmacoeconomic approach to antimicrobial formulary decision-making. Am J Health Syst Pharm 63: 735-739 [Abstract] [Full Text]  
  • Zelenitsky, S., Ariano, R., Harding, G., Forrest, A. (2005). Evaluating Ciprofloxacin Dosing for Pseudomonas aeruginosa Infection by Using Clinical Outcome-Based Monte Carlo Simulations. Antimicrob. Agents Chemother. 49: 4009-4014 [Abstract] [Full Text]  
  • Bhavnani, S. M., Hammel, J. P., Cirincione, B. B., Wikler, M. A., Ambrose, P. G. (2005). Use of Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Phase 2 and 3 Dosing Strategies for Doripenem. Antimicrob. Agents Chemother. 49: 3944-3947 [Abstract] [Full Text]  
  • Booker, B. M., Smith, P. F., Forrest, A., Bullock, J., Kelchlin, P., Bhavnani, S. M., Jones, R. N., Ambrose, P. G. (2005). Application of an In Vitro Infection Model and Simulation for Reevaluation of Fluoroquinolone Breakpoints for Salmonella enterica Serotype Typhi. Antimicrob. Agents Chemother. 49: 1775-1781 [Abstract] [Full Text]  
  • Mouton, J. W., Dudley, M. N., Cars, O., Derendorf, H., Drusano, G. L. (2005). Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 55: 601-607 [Abstract] [Full Text]  
  • Masterton, R. G., Kuti, J. L., Turner, P. J., Nicolau, D. P. (2005). The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe. J Antimicrob Chemother 55: 71-77 [Abstract] [Full Text]  
  • Lodise, T. P. Jr., Lomaestro, B., Rodvold, K. A., Danziger, L. H., Drusano, G. L. (2004). Pharmacodynamic Profiling of Piperacillin in the Presence of Tazobactam in Patients through the Use of Population Pharmacokinetic Models and Monte Carlo Simulation. Antimicrob. Agents Chemother. 48: 4718-4724 [Abstract] [Full Text]  
  • Mouton, J. W., Schmitt-Hoffmann, A., Shapiro, S., Nashed, N., Punt, N. C. (2004). Use of Monte Carlo Simulations To Select Therapeutic Doses and Provisional Breakpoints of BAL9141. Antimicrob. Agents Chemother. 48: 1713-1718 [Abstract] [Full Text]  
  • Alder, J., Li, T., Yu, D., Morton, L., Silverman, J., Zhang, X.-X., Critchley, I., Thorne, G. (2003). Analysis of Daptomycin Efficacy and Breakpoint Standards in a Murine Model of Enterococcus faecalis and Enterococcus faecium Renal Infection. Antimicrob. Agents Chemother. 47: 3561-3566 [Abstract] [Full Text]  
  • Ambrose, P. G., Bhavnani, S. M., Jones, R. N. (2003). Pharmacokinetics-Pharmacodynamics of Cefepime and Piperacillin- Tazobactam against Escherichia coli and Klebsiella pneumoniae Strains Producing Extended-Spectrum {beta}-Lactamases: Report from the ARREST Program. Antimicrob. Agents Chemother. 47: 1643-1646 [Abstract] [Full Text]  
  • Jones, R. N., Rubino, C. M., Bhavnani, S. M., Ambrose, P. G. (2003). Worldwide Antimicrobial Susceptibility Patterns and Pharmacodynamic Comparisons of Gatifloxacin and Levofloxacin against Streptococcus pneumoniae: Report from the Antimicrobial Resistance Rate Epidemiology Study Team. Antimicrob. Agents Chemother. 47: 292-296 [Abstract] [Full Text]  
  • Croisier, D., Chavanet, P., Lequeu, C., Ahanou, A., Nierlich, A., Neuwirth, C., Piroth, L., Duong, M., Buisson, M., Portier, H. (2002). Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones. J Antimicrob Chemother 50: 349-360 [Abstract] [Full Text]  
  • Drusano, G. L., Moore, K. H. P., Kleim, J. P., Prince, W., Bye, A. (2002). Rational Dose Selection for a Nonnucleoside Reverse Transcriptase Inhibitor through Use of Population Pharmacokinetic Modeling and Monte Carlo Simulation. Antimicrob. Agents Chemother. 46: 913-916 [Abstract] [Full Text]  
  • Ambrose, P. G., Owens, R. C. Jr, Garvey, M. J., Jones, R. N. (2002). Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime. J Antimicrob Chemother 49: 445-453 [Abstract] [Full Text]  
  • Montgomery, M. J., Beringer, P. M., Aminimanizani, A., Louie, S. G., Shapiro, B. J., Jelliffe, R., Gill, M. A. (2001). Population Pharmacokinetics and Use of Monte Carlo Simulation To Evaluate Currently Recommended Dosing Regimens of Ciprofloxacin in Adult Patients with Cystic Fibrosis. Antimicrob. Agents Chemother. 45: 3468-3473 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»